



Clarification statement

28 September 2020 – Perth, Australia: PharmAust Limited (ASX:PAA) refers to the ASX announcement released on 24 September 2020 advising that the Company has entered into a Service Agreement with Leiden University Medical Center (LUMC) in the Netherlands for LUMC to test the effects of monepantel and monepantel sulfone on the replication of SARS-CoV-2 in cell lines. PharmAust has been asked by ASX to confirm that it is a nominal fee that is not material to the company.

This announcement is authorised by the Board

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com